Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXRNASDAQ:LUNGNYSEAMERICAN:MYONASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.79+7.0%$8.26$6.55▼$10.00$44.26M-0.135,456 shs8,671 shsLUNGPulmonx$2.59-0.4%$3.42$2.50▼$9.37$104.67M0.52306,192 shs250,540 shsMYOMyomo$2.16-4.4%$3.35$2.15▼$7.17$81.31M1.49429,674 shs445,257 shsSGHTSight Sciences$4.13-4.0%$3.62$2.03▼$8.45$222.29M2.46212,188 shs85,457 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor+6.99%+3.49%+20.86%+20.27%+5.04%LUNGPulmonx-0.38%+0.78%-22.69%-62.30%-59.15%MYOMyomo-4.42%-4.85%-24.48%-55.46%-32.71%SGHTSight Sciences-3.95%-4.84%+11.32%+80.35%-38.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxor3.9283 of 5 stars3.53.00.00.02.23.30.0LUNGPulmonx3.283 of 5 stars3.33.00.00.03.33.30.6MYOMyomo3.1395 of 5 stars3.54.00.00.02.02.50.6SGHTSight Sciences1.1628 of 5 stars1.13.00.00.02.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00155.36% UpsideLUNGPulmonx 2.63Moderate Buy$11.53344.98% UpsideMYOMyomo 3.00Buy$9.13322.45% UpsideSGHTSight Sciences 2.29Hold$4.10-0.73% DownsideCurrent Analyst Ratings BreakdownLatest DXR, SGHT, MYO, and LUNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025MYOMyomoAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/23/2025MYOMyomoCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$10.00 ➝ $8.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.006/5/2025MYOMyomoAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $11.505/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.005/8/2025MYOMyomoCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/ALUNGPulmonx$83.79M1.24N/AN/A$2.17 per share1.19MYOMyomo$32.55M2.39N/AN/A$0.82 per share2.63SGHTSight Sciences$79.87M2.67N/AN/A$1.72 per share2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/ALUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)MYOMyomo-$6.18M-$0.23N/AN/AN/A-15.05%-35.57%-20.11%8/5/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.98N/AN/AN/A-63.24%-54.62%-34.92%7/30/2025 (Estimated)Latest DXR, SGHT, MYO, and LUNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AMYOMyomoN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/ALUNGPulmonx0.384.974.29MYOMyomoN/A2.662.37SGHTSight Sciences0.5110.479.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%LUNGPulmonx91.04%MYOMyomo44.99%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%LUNGPulmonx6.80%MYOMyomo4.54%SGHTSight Sciences28.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.96 millionNot OptionableLUNGPulmonx25040.26 million37.52 millionOptionableMYOMyomo9035.98 million34.35 millionNot OptionableSGHTSight Sciences21051.70 million36.76 millionOptionableDXR, SGHT, MYO, and LUNG HeadlinesRecent News About These CompaniesSight Sciences (NASDAQ:SGHT) Upgraded to Hold at Wall Street ZenJune 28 at 3:17 AM | americanbankingnews.comWall Street Zen Upgrades Sight Sciences (NASDAQ:SGHT) to "Hold"June 28 at 3:15 AM | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Receives $4.10 Consensus Target Price from AnalystsJune 27, 2025 | americanbankingnews.comSight Sciences Leads The Pack Of 3 Promising Penny StocksJune 24, 2025 | uk.finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by BrokeragesJune 24, 2025 | marketbeat.comPiper Sandler Raises Sight Sciences (NASDAQ:SGHT) Price Target to $4.00June 18, 2025 | marketbeat.comMillennium Management LLC Invests $464,000 in Sight Sciences, Inc. (NASDAQ:SGHT)June 10, 2025 | marketbeat.comsight sciences appoints new board member and holds annual meetingJune 7, 2025 | uk.investing.comSquarepoint Ops LLC Buys 128,355 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)June 4, 2025 | marketbeat.comSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27thMay 14, 2025 | globenewswire.comSight Sciences stock holds as Needham reiterates ratingMay 11, 2025 | uk.investing.comSight Sciences, Inc. (SGHT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comSight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue GuidanceMay 10, 2025 | finance.yahoo.comSight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 8, 2025 | zacks.comSight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comWhy Sight Sciences, Inc.’s (SGHT) Stock Is Down 5.02%April 26, 2025 | aaii.comASight Sciences appoints new board memberApril 24, 2025 | investing.comSight Sciences, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comQSight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comSight Sciences Announces the Release of its Sustainability ReportApril 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, SGHT, MYO, and LUNG Company DescriptionsDaxor NASDAQ:DXR$9.79 +0.64 (+6.99%) As of 06/30/2025 03:59 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Pulmonx NASDAQ:LUNG$2.59 -0.01 (-0.38%) As of 06/30/2025 04:00 PM EasternPulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Myomo NYSEAMERICAN:MYO$2.16 -0.10 (-4.42%) As of 06/30/2025 04:10 PM EasternMyomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Sight Sciences NASDAQ:SGHT$4.13 -0.17 (-3.95%) As of 06/30/2025 04:00 PM EasternSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
